Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Patent metadata

Field	Value
Publication number	US-11229676-B2
Application number	US-201916422520-A
Country	US
Kind code	B2
Filing date	May 24, 2019
Priority date	Dec 3, 2013
Publication date	Jan 25, 2022
Grant date	Jan 25, 2022

Abstract

It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G 0 /G 1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G 0 /G 1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.

First claim

We claim:

1. A method for detecting one or more kidney injury markers in a subject, the method comprising:
obtaining a body fluid sample collected from the subject within about 12 hours following a prophylactic treatment for acute kidney injury that uses cyclosporine A to induce G 0 /G 1 cell cycle arrest of renal epithelial cells; and
performing an assay on the body fluid sample, wherein the assay measures a concentration of one or more biomarkers to provide an assay result, wherein the one or more biomarkers consists of tissue inhibitor of metalloproteinases 2 (TIMP2) and wherein if the assay result is at least about 30% greater than a control level, the prophylactic treatment was successful.

2. The method according to claim 1 , wherein the prophylactic treatment uses one or more agents that inhibit apoptosis in combination with the cyclosporine A.

3. The method according to claim 2 , wherein the one or more agents that inhibit apoptosis comprise one or more glucocorticoids.

4. The method according to claim 1 , wherein the subject was selected for prophylactic treatment based on a pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal acute kidney injury.

5. The method according to claim 1 , wherein the subject was in RIFLE stage 0 or R at the time of the prophylactic treatment.

6. The method according to claim 1 , wherein the subject has sepsis.

7. The method according to claim 1 , wherein the body fluid sample is a urine sample.

8. The method according to claim 1 , wherein the prophylactic treatment was administered within 48 hours following an exposure to risk of kidney injury.

9. The method according to claim 1 , wherein the prophylactic treatment was in advance of an exposure to risk of kidney injury.

10. The method according to claim 1 , wherein the body fluid sample is obtained from the subject at about 6 hours after the prophylactic treatment.

11. A method for prophylactically treating a subject at risk of acute kidney injury and detecting one or more kidney injury markers in the prophylactically treated subject, the method comprising:
administering a prophylactic treatment comprising cyclosporine A to induce G 0 /G 1 cell cycle arrest of renal epithelial cells to the subject;
obtaining a body fluid sample collected from the subject within about 12 hours following the prophylactic treatment; and
performing an assay on the body fluid which measures a concentration of one or more biomarkers to provide an assay result, wherein the one or more biomarkers consists of tissue inhibitor of metalloproteinases 2 (TIMP2) and wherein if the assay result is at least about 30% greater than a control level, the prophylactic treatment was successful.

12. The method according to claim 11 , wherein the prophylactic treatment is administered within 48 hours following an exposure to risk of kidney injury.

13. The method according to claim 11 , wherein the prophylactic treatment is administered in advance of an exposure to risk of kidney injury.

14. The method of claim 13 , further comprising determining that the prophylactic treatment was successful prior to the exposure to risk of kidney injury.

15. The method of claim 14 , wherein the exposure to risk of kidney injury is an intervention, the method further comprising performing the intervention on the subject within about 48 hours after the prophylactic treatment, wherein the intervention comprises cardiac or vascular surgery or administering a nephrotoxic agent.

16. The method according to claim 11 , wherein the body fluid sample is obtained from the subject at about 6 hours after the prophylactic treatment.

Assignees

• Astute Medical Inc
• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education

Inventors

• Mcpherson Paul
• Kellum John A

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K38/13 Primary

  Cyclosporins · CPC title

• A61K31/453

  containing a six-membered ring with oxygen as a ring hetero atom · CPC title

• G01N2333/4745

  Insulin-like growth factor binding protein · CPC title

• A61K31/436

  the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin · CPC title